glp 1 drugs for alcohol use disorder A new clinical trial supported by the National Institutes of Health (NIH) found that a medication commonly used weight loss, such as semaglutide, may also help reduce heavy drinking in individuals APA TV x Psychiatric News

Finally, there is a marked inverse relationship between albuminuria and CKD regression/clinical outcomes, meaning that the higher the levels of albuminuria, the lower the chances of the kidney regaining some of its function, and vice versa, thus making albuminuria a suitable biomarker of CKD [39]

Considerable interest exists in identifying effects of these drugs beyond glucose-lowering, possibly resulting in improved macrovascular and microvascular outcomes, including in diabetic kidney disease

Research on NAD+ supplementation, usually through precursors like NMN or NR, suggests potential benefits for anti-aging and cellular health

Our study using 2020 to 2025 Medicare data showed dramatic increases in out-of-pocket costs for GLP-1s, because of insurers reactions to the 2022 Inflation Reduction Act

Nancy Shenoi, M.D., assistant professor of psychiatry at Baylor College of Medicine, pointed out gaps in obesity treatment in low- and middle-income countries and rural areas